NHS National Generics Pharmaceuticals - Dasatinib and Paliperidone Injection

Invitation to offer for NHS National Generic Pharmaceuticals - Dasatinib and Paliperidone Injection

Offer reference number: CM/PHG/22/5694

FIND A TENDER (FTS) Reference number

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 21 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months.

Potential periods of call-offs under the framework agreement:

CM/PHG/22/5694/00 - Dasatinib

CESW 01/05/2023 - 30/04/2024 - (12 Months)

LSNE 01/05/2023 - 30/04/2024 - (12 Months)

NWLN 01/05/2023 - 30/04/2024 - (12 Months)

CM/PHG/22/5694/01 - Paliperidone Injection:

LSNE 01/05/2023 - 31/05/2024 (13 Months)

NWLN 01/05/2023 - 31/01/2025 (21 months)

Tender Documents

• Opportunity notice on Contracts Finder → — Tender notice
• Document No. 00 - Read Me First Document →
• Document No. 01 - Invitation to offer covering letter →
• Document No. 02 - Terms of offer →
• Document No. 03 - Framework Agreement and Terms and Conditions →
• Document No. 05a(iv) CM_PHG_22_5694_01 →
• Document No. 05b - Selectt offer schedule instructions →
• Document No. 07b - Quality Assurance Policy to support the National Contract Procurement of Licensed Medicines - Edition 5.1 September 2022 →
• Document No. 08 - Confidential information schedule →
• Document No. 04a - Quality Assurance Process →
• Document No. 04b - Assessment Criteria, Stability Protocol and Additional Specification Requirements →
• Document No. 05a(i) - Tender Product Listing and Usage - Dasatinib →
• Document No. 05a(ii) CM_PHG_22_5694_00 →
• Document No. 05a(iii) - Tender Product Listing and Usage - Paliperidone →
• Document No. 06 - Form of offer →